Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 22 January 2013 | By Louise Zornoza
Brazil's national regulatory authority, Anvisa, has opened a Public Consultation on proposed revisions to the criteria for the technical requirements for quality, safety and efficacy needed to support the registration of new, generic and biosimilar medicines.
The consultation, released on 8 January 2013, would replace Resolutions RDC No. 136/2003, RDC No. 16/2007 and RDC No. 17/2007, whose update was prompted by new technological developments.
The deadline for comments on the consultation is 5 April 2013.
Read all Breaking News from RegLink
Tags: Generic, Latest News, pharmaceutical, brazil, registration, biosimilar, drug